Log in to save to my catalogue

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immuno...

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immuno...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_11a7498d8b624c7f9293ade72a94e6d3

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

About this item

Full title

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2023-04, Vol.14 (1), p.2020-2020, Article 2020

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the potential to overcome manufacturing bottlenecks, they are subject to immune rejection and failure to persist in the host, and thus do no...

Alternative Titles

Full title

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_11a7498d8b624c7f9293ade72a94e6d3

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_11a7498d8b624c7f9293ade72a94e6d3

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-023-37785-2

How to access this item